Back to Search
Start Over
Endothelin receptor antagonists: current status and perspectives
- Source :
- Journal of cardiovascular pharmacology. 35(4 Suppl 2)
- Publication Year :
- 2000
-
Abstract
- Endothelin (ET) receptor antagonists have been proposed for the treatment of a variety of disorders where ET may act as a pathogenic mediator. The rationale is very strong in certain diseases, where ET concentrations are increased and where ET receptor antagonists have shown efficacy in experimental conditions. However, clinical studies are needed to prove that this approach is effective in the clinical setting. Because there are still very few ET receptor antagonists in clinical development, proof of concept studies in clinical situations have been performed only in a small number of indications. We describe here the preclinical and clinical results obtained with the first orally active ET receptor antagonist in three therapeutic fields, congestive heart failure, systemic hypertension and cerebral vasospasm. The encouraging clinical results obtained support a further clinical development of ET receptor antagonists in these three indications.
- Subjects :
- Endothelin Receptor Antagonists
medicine.drug_class
Pharmacology
Mediator
Medicine
Animals
Humans
Vasospasm, Intracranial
Receptor
Antihypertensive Agents
Heart Failure
Sulfonamides
business.industry
Antagonist
Bosentan
Subarachnoid Hemorrhage
Receptor antagonist
medicine.disease
Mechanism of action
Heart failure
Hypertension
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Endothelin receptor
medicine.drug
Subjects
Details
- ISSN :
- 01602446
- Volume :
- 35
- Issue :
- 4 Suppl 2
- Database :
- OpenAIRE
- Journal :
- Journal of cardiovascular pharmacology
- Accession number :
- edsair.doi.dedup.....36992cdac19181c82fd2b245a4bd60a2